Analyze Diet

Topic:Vaccine

Vaccination in horses involves the administration of biological preparations designed to stimulate the equine immune system to recognize and combat specific pathogens. Vaccines are formulated to prevent or reduce the severity of infectious diseases that can affect equine health and performance. Common vaccines for horses include those for equine influenza, tetanus, equine herpesvirus, and West Nile virus. The administration schedule and type of vaccine can vary based on factors such as geographic location, age, and use of the horse. This page compiles peer-reviewed research studies and scholarly articles that explore the development, efficacy, and safety of vaccines in horses, as well as their impact on equine health management.
Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
Clinical and vaccine immunology : CVI    August 8, 2007   Volume 14, Issue 11 1465-1471 doi: 10.1128/CVI.00249-07
Seino KK, Long MT, Gibbs EP, Bowen RA, Beachboard SE, Humphrey PP, Dixon MA, Bourgeois MA.We used a severe challenge model that produces clinical West Nile virus (WNV) disease to test the efficacy of three commercially available equine WNV vaccines in horses. Twenty-four healthy, WNV-seronegative horses of varying ages and genders were placed, in random and blind manner, into three trial groups consisting of eight horses each; two horses in each group received (i) an inactivated WNV vaccine (K-WN), (ii) a modified-live vaccine (CP-WN) containing the WNV prM and E proteins expressed by a canarypox vector, (iii) a live-chimera vaccine (WN-FV) containing WNV prM and E proteins express...
Evidence-based immunization in horses.
The Veterinary clinics of North America. Equine practice    July 10, 2007   Volume 23, Issue 2 481-508 doi: 10.1016/j.cveq.2007.04.003
Barquero N, Gilkerson JR, Newton JR.Evidence of vaccine efficacy is essential for practitioners when giving advice to clients about the relative merits of different vaccines or when trying to evaluate the economic benefits of instituting a vaccine program. In equine veterinary medicine, this sort of data, which are necessary to make informed decisions about vaccine use and effectiveness, are often not available. Veterinarians need to consider the epidemiology of the disease in question, the type of vaccine that they are administering to the animal, the immunologic constraints of the vaccine technology, and the available evidence...
Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine.
Journal of comparative pathology    June 7, 2007   Volume 137 Suppl 1 S76-S80 doi: 10.1016/j.jcpa.2007.04.016
Minke JM, Toulemonde CE, Dinic S, Cozette V, Cullinane A, Audonnet JC.A classical limitation of early life immunization is the interference by maternally derived antibodies, which are known to inhibit the immune response to modified-live and killed vaccines. Several studies have convincingly shown that even minute amounts of maternally derived antibodies against equine influenza can strongly interfere with successful vaccination of foals born to immune mares. In this study we evaluated the response of foals born to vaccinated mares to immunization with a canarypox-vectored recombinant vaccine against equine influenza virus H3N8. The recombinant vaccine was able ...
Immune responsiveness in the neonatal period.
Journal of comparative pathology    June 4, 2007   Volume 137 Suppl 1 S27-S31 doi: 10.1016/j.jcpa.2007.04.008
Morein B, Blomqvist G, Hu K.The maintenance of pregnancy requires suppression of the maternal immune system which would naturally recognize the developing fetus as an allograft and seek to destroy it by mounting a Th1 regulated cytotoxic immune response. During pregnancy a range of soluble factors are produced by the placenta which switch maternal immune regulation towards a protective Th2 phenotype. These factors also influence the developing fetal immune system and all newborns initially have an immunological milieu skewed towards Th2 immunity. Vaccination during the neonatal period must therefore overcome the dual cha...
Modified live Streptococcus equi (‘strangles’) vaccination followed by clinically adverse reactions associated with bacterial replication.
Equine veterinary journal    May 25, 2007   Volume 39, Issue 3 284-286 doi: 10.2746/042516407x195961
Kemp-Symonds J, Kemble T, Waller A.No abstract available
Strangles vaccines in trouble again.
Equine veterinary journal    May 25, 2007   Volume 39, Issue 3 196 doi: 10.2746/042516407x196744
Timoney JF.No abstract available
Long terminal repeat sequences from virulent and attenuated equine infectious anemia virus demonstrate distinct promoter activities.
Virus research    May 11, 2007   Volume 128, Issue 1-2 58-64 doi: 10.1016/j.virusres.2007.04.005
Zhou T, Yuan XF, Hou SH, Tu YB, Peng JM, Wen JX, Qiu HJ, Wu DL, Chen HC, Wang XJ, Tong GZ.In the early 1970s, the Chinese Equine Infectious Anemia Virus (EIAV) vaccine, EIAV(DLA), was developed through successive passages of a wild-type virulent virus (EIAV(L)) in donkeys in vivo and then in donkey macrophages in vitro. EIAV attenuation and cell tropism adaptation are associated with changes in both envelope and long terminal repeat (LTR). However, specific LTR changes during Chinese EIAV attenuation have not been demonstrated. In this study, we compared LTR sequences from both virulent and attenuated EIAV strains and documented the diversities of LTR sequence from in vivo and in v...
Investigation of the molecular detection of vaccine-derived equine herpesvirus type 1 in blood and nasal secretions from horses following intramuscular vaccination. Pusterla N, Chaney KP, Maes R, Wise AG, Holland R, Schott HC.The objective of this study was to investigate whether intramuscular vaccination of healthy adult horses with a killed or a modified live equine herpesvirus type 1 (EHV-1) vaccine could induce transient positive PCR results in either blood or secretions collected on a nasopharyngeal swab. Four horses in each group received either a single killed or a modified-live vaccine intramuscularly. Two local commingled and 2 distant nonvaccinated controls were included for each group. All horses were observed daily for evidence of clinical abnormalities throughout the study periods. Blood and nasopharyn...
An epidemiological investigation of the African horsesickness outbreak in the Western Cape Province of South Africa in 2004 and its relevance to the current equine export protocol.
Journal of the South African Veterinary Association    April 27, 2007   Volume 77, Issue 4 191-196 doi: 10.4102/jsava.v77i4.376
Sinclair M, Bührmann G, Gummow B.African Horsesickness (AHS) is a controlled disease in South Africa. The country is divided into an infected area and a control area. An outbreak of AHS in the control area can result in a ban of exports for at least 2 years. A retrospective epidemiological study was carried out on data collected during the 2004 AHS outbreak in the surveillance zone of the AHS control area in the Western Cape Province. The objective of this study was to describe the 2004 outbreak and compare it with the 1999 AHS outbreak in the same area. As part of the investigation, a questionnaire survey was conducted in th...
Evidence for transferrin allele as a host-level risk factor in naturally occurring equine respiratory disease: a preliminary study.
Equine veterinary journal    March 24, 2007   Volume 39, Issue 2 164-171 doi: 10.2746/042516407x166954
Newton JR, Woodt JL, Chanter N.Recurring respiratory infections can contribute to prolonged burdens of disease, especially in younger horses and better knowledge of factors and effective interventions, such as vaccines, should improve therapeutic and preventive strategies. Objective: To identify factors and infections associated with naturally occurring respiratory disease in recently weaned Welsh Mountain ponies maintained at pasture and to determine whether ponies vaccinated with an experimental inactivated bacterial vaccine had lower burdens of disease and infection compared to nonvaccinated controls. Transferrin allele,...
Avian titer development against West nile virus after extralabel use of an equine vaccine.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians    February 28, 2007   Volume 36, Issue 2 257-264 doi: 10.1638/03-094.1
Johnson S.West Nile virus affects many animals, but the highest prevalence of morbidity and mortality is observed in birds, horses, and humans. The purpose of this study was to determine a protocol in birds of prey and corvids, using a vaccine developed for horses. The birds were assigned to five groups. Groups 1-4 received 0.25 ml, 0.5 ml, 0.75 ml, and 1.0 ml, respectively, and group 5 served as a control group. The greatest percentage of seroconversion (58.3%) was observed in the vaccine group that received a dose of 1.0 ml administered thrice, 3 wk apart. This report demonstrates that a vaccine devel...
Correlation between the induction of Th1 cytokines by an attenuated equine infectious anemia virus vaccine and protection against disease progression.
The Journal of general virology    February 28, 2007   Volume 88, Issue Pt 3 998-1004 doi: 10.1099/vir.0.82416-0
Zhang X, Wang Y, Liang H, Wei L, Xiang W, Shen R, Shao Y.The equine infectious anemia virus (EIAV) donkey-leukocyte attenuated vaccine (DLV) has been used to protect against equine infectious anaemia (EIA) disease for several decades in China. The attenuated mechanism and immunological protective mechanisms remain to be elucidated. To identify responses that correlate with the protection against disease, we immunized horses with DLV, followed by challenge with an EIAV wild-type strain LN. All vaccinated horses were asymptomatic and had a low level of virus replication (<10 copies ml-1). The expression level of cytokines including gamma interferon...
Evidence of the partial effects of inactivated Japanese encephalitis vaccination: analysis of previous outbreaks in Japan from 1953 to 1960.
Annals of epidemiology    February 14, 2007   Volume 17, Issue 4 271-277 doi: 10.1016/j.annepidem.2006.10.003
Satou K, Nishiura H.To evaluate the partial effects of vaccination against equine Japanese encephalitis (JE) and characterize other prognostic factors based on previous outbreak records in Japan from 1953 to 1960. Methods: Individual case records, which included demographic information, vaccination history, and clinical information (dates of onset, recovery and death, and symptoms), were investigated. The relations between two outcomes, JE death and symptomatic period, and other variables were examined. Results: Of a total reported 803 cases during the observation period, 453 (56.5%) were diagnosed with either se...
Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California.
Veterinary research    February 6, 2007   Volume 38, Issue 1 109-116 doi: 10.1051/vetres:2006045
Gardner IA, Wong SJ, Ferraro GL, Balasuriya UB, Hullinger PJ, Wilson WD, Shi PY, MacLachlan NJ.A prospective cohort study was used to estimate the incidence of West Nile virus (WNV) infection in a group of unvaccinated horses (n = 37) in California and compare the effects of natural WNV infection in these unvaccinated horses to a group of co-mingled vaccinated horses (n = 155). Horses initially were vaccinated with either inactivated whole virus (n = 87) or canarypox recombinant (n = 68) WNV vaccines during 2003 or 2004, prior to emergence of WNV in the region. Unvaccinated horses were serologically tested for antibodies to WNV by microsphere immunoassay incorporating recombinant WNV E ...
Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
Virus research    January 22, 2007   Volume 125, Issue 1 69-78 doi: 10.1016/j.virusres.2006.12.009
Rosas CT, Tischer BK, Perkins GA, Wagner B, Goodman LB, Osterrieder N.The immunogenicity in horses of a recombinant equine herpesvirus type 1 (EHV-1) vaccine expressing West Nile virus (WNV) prM and E proteins was studied. To construct the recombinant EHV-1, two-step en passant mutagenesis was employed for manipulation of a bacterial artificial chromosome (BAC) of vaccine strain RacH. Recombinant EHV-1 stably expressed the WNV prM and E proteins as demonstrated by indirect immunofluorescence and Western blotting. In addition, growth properties in vitro of the EHV-1/WNV recombinant were found to not be significantly different from those of the parental virus. To ...
Vaccination of horses against strangles using recombinant antigens from Streptococcus equi.
Vaccine    January 22, 2007   Volume 25, Issue 18 3629-3635 doi: 10.1016/j.vaccine.2007.01.060
Waller A, Flock M, Smith K, Robinson C, Mitchell Z, Karlström A, Lannergård J, Bergman R, Guss B, Flock JI.Strangles is an upper respiratory tract infection in horses, which is highly contagious and one of the more costly diseases of the horse. Three recombinant antigens were used to vaccinate horses, which were then experimentally challenged with Streptococcus equi, the causative agent for strangles. The vaccinated horses showed significantly reduced bacterial growth (p=0.02) and nasal discharge (p=0.0004), a typical symptom of strangles. Other clinical signs of strangles were also reduced and at post mortem examination, lower rate of empyaema or scarring of the guttural pouches was found in the v...
West Nile virus: recent trends in diagnosis and vaccine development.
Vaccine    December 22, 2006   Volume 25, Issue 30 5563-5576 doi: 10.1016/j.vaccine.2006.12.005
Dauphin G, Zientara S.West Nile virus (WNV) is a mosquito-borne flavivirus, native to Africa, Europe, and Western Asia. In many respects, WNV is an outstanding example of a zoonotic pathogen that has leaped geographical barriers and can cause severe disease in human and horse. Before the emergence of WNV in the USA, only few methods of diagnosis were available. Recently, many changes in the fields of WN diagnosis and prevention have happened. This paper will review all these new tools. After a description of the main concerns in WNV and West Nile (WN) disease in humans and animals, this review will present the main...
Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.
Vaccine    December 8, 2006   Volume 25, Issue 30 5606-5612 doi: 10.1016/j.vaccine.2006.11.066
Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC.The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk...
An outbreak of equine influenza virus in vaccinated horses in Italy is due to an H3N8 strain closely related to recent North American representatives of the Florida sub-lineage.
Veterinary microbiology    November 25, 2006   Volume 121, Issue 1-2 56-63 doi: 10.1016/j.vetmic.2006.11.017
Martella V, Elia G, Decaro N, Di Trani L, Lorusso E, Campolo M, Desario C, Parisi A, Cavaliere N, Buonavoglia C.In December 2005, equine influenza virus infection was confirmed as the cause of clinical respiratory disease in vaccinated horses in Apulia, Italy. The infected horses had been vaccinated with a vaccine that contained strains representatives from both the European (A/eq/Suffolk/89) and American (A/eq/Newmarket/1/93) H3N8 influenza virus lineages, and the H7N7 strain A/eq/Praga/56. Genetic characterization of the hemagglutinin (HA) and neuraminidase (NA) genes of the virus from the outbreak, indicated that the isolate (A/eq/Bari/2005) was an H3N8 strain closely related to recent representative...
Equine botulism and acute pasture myodystrophy: new soil-borne emerging diseases in Switzerland?
Schweizer Archiv fur Tierheilkunde    November 2, 2006   Volume 148, Issue 10 553-559 doi: 10.1024/0036-7281.148.10.553
Gerber V, Straub R, Frey J.In Switzerland, the incidence of equine botulism and acute pasture myodystrophy have remarkably increased in the last five years. Equine fodder-borne botulism in Europe is most likely caused by Clostridium botulinum types C and D that produce the toxins BoNT/C and BoNT/D. Horses showing signs suggestive of botulism (muscle weakness and tremors, reduced tongue tone, slow chewing, salivation and difficulties swallowing, drooping eyelids, mydriasis), especially patients that have fed on suspect fodder (mostly haylage), must be treated with anti-serum as soon as possible. They also need intensive ...
Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses.
Veterinary therapeutics : research in applied veterinary medicine    October 14, 2006   Volume 7, Issue 3 249-256 
Siger L, Bowen R, Karaca K, Murray M, Jagannatha S, Echols B, Nordgren R, Minke JM.Efficacy of the Recombitek Equine West Nile Virus (WNV) vaccine was evaluated against a WNV intrathecal challenge model that results in WNV-induced clinical disease. Ten vaccinated (twice at days 0 and 35) and 10 control horses were challenged 2 weeks after administration of the second vaccine with a virulent WNV by intrathecal administration. After the challenge, eight of 10 controls developed clinical signs of encephalomyelitis whereas one vaccinate exhibited muscle fasciculation only once. Nine controls and one vaccinate developed a fever. Histopathology revealed mild to moderate nonsuppura...
Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.
Vaccine    September 22, 2006   Volume 25, Issue 5 834-845 doi: 10.1016/j.vaccine.2006.09.040
Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, Issel CJ, Montelaro RC.We previously reported that an experimental live-attenuated equine infectious anemia virus (EIAV) vaccine, containing a mutated S2 accessory gene, provided protection from disease and detectable infection after virulent virus (EIAV(PV)) challenge [Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, et al. A live-attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003;77(13):7244-53; Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L...
Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine.
Veterinary immunology and immunopathology    September 6, 2006   Volume 114, Issue 1-2 103-110 doi: 10.1016/j.vetimm.2006.07.013
Lopez AM, Hecker R, Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA, Townsend HG.Previous studies have shown that protection against equine influenza virus (EIV) is partially mediated by virus-specific IgGa and IgGb. In this study we tested whether addition of a CpG ODN formulation to a commercial killed virus vaccine would enhance EIV-specific IgGa and IgGb antibody responses, and improve protection against an experimental EIV challenge. Thirty naïve horses were assigned to one of three groups and vaccinated as follows: 10 were given vaccine (Encevac TC4, Intervet Inc.) alone, 10 were given vaccine plus 0.25 mg CpG ODN 2007 formulated with 30% Emulsigen (CpG/Em), and 10 ...
Superovulation in mares.
Animal reproduction science    June 12, 2006   Volume 99, Issue 1-2 1-8 doi: 10.1016/j.anireprosci.2006.04.054
Squires EL, McCue PM.Embryo recovery from single ovulating mares is approximately 50 per cent per estrous cycle. Superovulation could be used to increase embryo recovery and provide extra embryos for embryo freezing. This review addresses some historical approaches to superovulation, as well as examines factors that affect the response of mares to equine FSH. eCG, GnRH and inhibin vaccines have been of limited success in stimulating multiple ovulation. Numerous studies have shown that injection of equine pituitary extract (EPE) will result in three to four ovulations per estrous cycle and two embryos. A purified, ...
Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
Veterinary immunology and immunopathology    April 18, 2006   Volume 112, Issue 3-4 225-233 doi: 10.1016/j.vetimm.2006.02.007
Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM.In horses, equine influenza virus (EIV) is a leading cause of respiratory disease. Conventional inactivated vaccines induce a short-lived immune response. By comparison, natural infection confers a long-term immunity to re-infection. An aim of new equine influenza vaccines is to more closely mimic natural infection in order to achieve a better quality of immunity. A new live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) has been developed. Stimulation of the immune system was studied after immunisation with this canarypox-...
West Nile virus in the United States (1999-2005).
Journal of the American Animal Hospital Association    April 14, 2006   Volume 42, Issue 3 170-177 doi: 10.5326/0420170
Gerhardt R.The accidental introduction of West Nile Virus into New York City from the Old World in 1999 resulted in an epidemic in humans, horses, and birds that swept to the west coast in just 3 years. The virus is transmitted by infective mosquitoes among susceptible native birds, which serve as amplifying hosts. Clinical disease occurs in humans and horses, but not enough virus is produced in their blood to infect other mosquitoes; therefore, humans and horses are considered dead-end hosts. Humans can best protect themselves by remaining indoors during periods of high mosquito activity and/or by using...
Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
Veterinary immunology and immunopathology    March 31, 2006   Volume 111, Issue 1-2 47-57 doi: 10.1016/j.vetimm.2006.01.008
Minke JM, Fischer L, Baudu P, Guigal PM, Sindle T, Mumford JA, Audonnet JC.In this study, experimental canarypox virus (ALVAC) and plasmid DNA recombinant vaccines expressing the gB, gC and gD glycoproteins of EHV-1 were assessed for their ability to protect conventional ponies against a respiratory challenge with EHV-1. In addition, potential means of enhancing serological responses in horses to ALVAC and DNA vaccination were explored. These included co-administration of the antigen with conventional adjuvants, complexation with DMRIE-DOPE and co-expression of the antigen along with equine GM-CSF. Groups of EHV primed ponies were vaccinated twice intra-muscularly wi...
Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004.
Veterinary immunology and immunopathology    March 20, 2006   Volume 111, Issue 1-2 3-13 doi: 10.1016/j.vetimm.2006.01.004
Slater JD, Lunn DP, Horohov DW, Antczak DF, Babiuk L, Breathnach C, Chang YW, Davis-Poynter N, Edington N, Ellis S, Foote C, Goehring L, Kohn CW....Amongst the infectious diseases that threaten equine health, herpesviral infections remain a world wide cause of serious morbidity and mortality. Equine herpesvirus-1 infection is the most important pathogen, causing an array of disorders including epidemic respiratory disease abortion, neonatal foal death, myeloencephalopathy and chorioretinopathy. Despite intense scientific investigation, extensive use of vaccination, and established codes of practice for control of disease outbreaks, infection and disease remain common. While equine herpesvirus-1 infection remains a daunting challenge for i...
Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
Veterinary immunology and immunopathology    February 28, 2006   Volume 111, Issue 1-2 97-108 doi: 10.1016/j.vetimm.2006.01.012
Foote CE, Raidal SL, Pecenpetelovska G, Wellington JE, Whalley JM.We have previously demonstrated that intramuscular inoculation of EHV-1 glycoprotein D (gD) and glycoprotein B (gB) produced by a recombinant baculovirus and formulated with the adjuvant Iscomatrix elicited virus-neutralizing antibody and gD- and gB-specific ELISA antibody in adult horses. In this study, 14 mares and their very young foals were inoculated with a combination of baculovirus-expressed EHV-1 gD and EHV-1 gB (EHV-1 gDBr) and challenged with a respiratory strain of EHV-1. Following experimental challenge, inoculated mares and foals shed virus in nasal secretions on significantly few...
EHV-1 and EHV-4 infection in vaccinated mares and their foals.
Veterinary immunology and immunopathology    February 28, 2006   Volume 111, Issue 1-2 41-46 doi: 10.1016/j.vetimm.2006.01.007
Foote CE, Love DN, Gilkerson JR, Wellington JE, Whalley JM.A silent cycle of equine herpesvirus 1 infection was described following epidemiological studies of unvaccinated mares and foals on a Hunter Valley stud farm. Following the introduction of routine vaccination with an inactivated whole virus equine herpesvirus 1 (EHV-1) and equine herpesvirus 4 (EHV-4) vaccine in 1997, a subsequent study identified excretion of EHV-1 and EHV-4 in nasal swab samples tested by PCR from vaccinated mares and their unweaned, unvaccinated foals. The current sero-epidemiological investigation of vaccinated mares and their young foals found serological evidence of EHV-...
1 15 16 17 18 19 30